Oral Cardiac Drug-Gut Microbiota Interaction in Chronic Heart Failure Patients: An Emerging Association

Int J Mol Sci. 2024 Jan 31;25(3):1716. doi: 10.3390/ijms25031716.

Abstract

Regardless of the currently proposed best medical treatment for heart failure patients, the morbidity and mortality rates remain high. This is due to several reasons, including the interaction between oral cardiac drug administration and gut microbiota. The relation between drugs (especially antibiotics) and gut microbiota is well established, but it is also known that more than 24% of non-antibiotic drugs affect gut microbiota, altering the microbe's environment and its metabolic products. Heart failure treatment lies mainly in the blockage of neuro-humoral hyper-activation. There is debate as to whether the administration of heart-failure-specific drugs can totally block this hyper-activation, or whether the so-called intestinal dysbiosis that is commonly observed in this group of patients can affect their action. Although there are several reports indicating a strong relation between drug-gut microbiota interplay, little is known about this relation to oral cardiac drugs in chronic heart failure. In this review, we review the contemporary data on a topic that is in its infancy. We aim to produce scientific thoughts and questions and provide reasoning for further clinical investigation.

Keywords: drug interaction; gut microbiota; heart failure.

Publication types

  • Review

MeSH terms

  • Cardiovascular Agents* / therapeutic use
  • Chronic Disease
  • Dysbiosis / drug therapy
  • Gastrointestinal Microbiome* / physiology
  • Heart
  • Heart Failure* / drug therapy
  • Humans
  • Microbiota*

Substances

  • Cardiovascular Agents

Grants and funding

This research received no external funding.